top of page
Human brain on a dark blue background
Broadreach Global logo white
BIO NEUROSCIENCE 2_NO BG

14 - 15 February

2024

Amsterdam

The Netherlands

The partnering and investment summit for global leaders in CNS neuroscience drug discovery and development.

 TM

Welcome
  • LinkedIn
  • Twitter

SHARE

About
Fabulous, incredibly beautiful magical landscape with a river and tulips in Amsterdam, Hol
ABOUT
Insight - Innovation - Access - Engagement - Partnering

The global partnering and investment summit for global leaders and innovators in CNS neuroscience and psychiatric drug discovery, development, platforms and technologies.

Convened by-invitation, Bio-Neuroscience is a high level, boutique
gathering of key thought leaders, innovators and decision-makers from all key stakeholder groups crucial to the discovery, development and market launch of novel therapeutics and breakthrough platforms and technologies.

High level access, serious, sustained engagement, discussion and networking with key stakeholders. Sharing models, lessons learned, solutions, ways forward and best practices. A truly curated and unique summit to facilitate business and accelerate innovation. 

 
Amsterdam by Tobias Kordt

ADVISORY BOARD

Advisory Board

We are honored by the support of our Advisory Board.

Meet them in person at the summit.

Stacie Weninger

Stacie Weninger

Executive Director - F-Prime Biomedical Research Initiative

David Reynolds

David Reynolds

Venture Partner - SV Health Investors, CEO - LoQus23 Therapeutics

Sourav Kole

Sourav Kole

Managing Director - Dolby Family Ventures

Joachim Scholpp

Joachim Scholpp

Global Head Translational Medicine CNS & Emerging Areas - Boehringer Ingelheim

Kalpana Merchant, PhD

Kalpana Merchant, PhD

Chief Scientific Officer - Retromer Therapeutics, Adjunct Professor of Neurology - Northwestern University Feinberg School of Medicine.

Juan Carlos Lopez

Juan Carlos Lopez

Managing Director, Research Grants - RTW Charitable Foundation. Formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience

Mark Treherne

Mark Treherne

Commercial Scientist, Entrepreneur & Investor. Chairperson - Monument Therapeutics, Talisman Therapeutics, Ubiqent, NuVision Biotherapies

Pieter van Bokhoven

Pieter van Bokhoven

Chief Scientific Officer - Amsterdam Neuroscience IAO - VUMC

Andrea Soto Padilla, M.D. PhD

Andrea Soto Padilla, M.D. PhD

Business Development - Amsterdam UMC

Pawel Świeboda

Pawel Świeboda

Founder - NeuroCentury; Practice Lead Neurotechnology, ICFG; Senior Advisor on Brain Health, FIPRA.

Hakan Goker

Hakan Goker

Managing Director, Head of Healthcare & Life Sciences - M-Ventures

Christian J. Suojanen

Christian J. Suojanen

Founder & CEO - Broadreach Global, Member of the Board - European Brain Foundation

Bikes at Amsterdam Canal

SPEAKERS

Speakers

Meet the speakers:

Florian Brand

Florian Brand

CEO & Co-Founder - atai Life Sciences

Mary Chamberlain-Tharp

Mary Chamberlain-Tharp

Chief Business Officer – Neumora

Philip Scheltens

Philip Scheltens

Head of the Dementia Fund, Partner - EQT Life Sciences, Professor of Neurology - Amsterdam University Medical Center

Olga Krylova

Olga Krylova

Director Of Business Development & Innovation - Otsuka Pharmaceutical Companies Europe

Christian Thomsen

Christian Thomsen

Global Head of CNS BD&L - Boehringer Ingelheim

Raúl Martín-Ruiz

Raúl Martín-Ruiz

Partner - Ysios Capital

Claire Leurent

Claire Leurent

Managing Director - Abbvie Ventures

Cillian King

Cillian King

Managing Director - EQT Life Sciences

Jasper Bos

Jasper Bos

General Partner - Forbion

Martien Kas

Martien Kas

President - European College of NeuroPsychopharmacology (ECNP), Professor of Behavioral Neuroscience - Groningen Institute for Evolutionary Life Sciences, University of Groningen

Dee Datta

Dee Datta

CEO - Switch Therapeutics

Niels Plath

Niels Plath

Chief Scientific Officer - Muna Therapeutics

José Luis Lanciego

José Luis Lanciego

Chair - International Brain Research Organization Pan-European Committee, Head, Laboratory of Functional Neuroanatomy of the Basal Ganglia, CNS Gene Therapy Program - CIMA, University of Navarra

Kees Been

Kees Been

Chief Executive Officer - Kynexis Therapeutics, Inc

Aaron Koenig

Aaron Koenig

Chief Medical Officer - Delix Therapeutics

Craig Thompson

Craig Thompson

Chief Executive Officer - Cerevance

Maria Luisa Pineda

Maria Luisa Pineda

CEO & Co-Founder - Envisagenics

Jim Sullivan

Jim Sullivan

Co-Founder & CEO - Vanqua Bio

Yael Weiss

Yael Weiss

CEO - Mahzi Therapeutics

Frédéric Destrebecq

Frédéric Destrebecq

Executive Director - European Brain Council

Terry Pirovolakis

Terry Pirovolakis

Founder & CEO - Elpida Therapeutics

Anela Vukoja

Anela Vukoja

COO - Apollo Health Ventures

Carlos Buesa

Carlos Buesa

Founder & Chairman of the Board - Oryzon

John Kastelein

John Kastelein

CSO - New Amsterdam Pharma, Operating Partner - Forbion,

Anta Gkelou

Anta Gkelou

Principal - Sofinnova Partners (to be confirmed)

Jason Dictenberg

Jason Dictenberg

CEO – SpliceRNA, Advisory Board Member – Alzheimers Drug Discovery Foundation, New York

Arno de Wilde

Arno de Wilde

Director - EQT Life Sciences

Rowan Gardner

Rowan Gardner

Co-founder and Chief Business & Investment Officer - PrecisionLife

Hilgo Bruining

Hilgo Bruining

Professor, Neurobiological developmental disorders -Amsterdam UMC. Head - N=You Neurodevelopmental Precision Center

Delphine Charvin

Delphine Charvin

Operating Partner - ARGOBIO Studio

Participants

WHO'S COMING?

Two days of sustained, interactive discussion, networking and partnering with:

Female Presenter

Industry Leaders

Senior industry leaders from pharma, large biotech and healthcare companies. Heads of therapeutic area, R&D, clinical development, biological sciences,  M&A, scouting, business development & licensing.

Andy Keller keynote

Key Opinion Leaders

Key Opinion Leaders from all stakeholder groups crucial to the successful development, approval and market launch of novel CNS neuroscience and psychiatric therapeutics, platforms and technologies.

Josh Scholpp speaking

Founders & CEOs

From startup and growth companies at the cutting edge of the future of CNS neuroscience and psychiatric drug discovery, development, advanced therapies, platforms and technologies. 

Country Flags

Government & NGOs

Public agencies, funding bodies, foundations, societies, associations, patient organizations & NGOs in CNS neurosciences and psychiatry.

FA61F746-487A-4B2A-A330-799B71754219_ed

Investors

In CNS neuroscience and psychiatric drug development, platforms and technologies.

VC and corporate venture, private equity, family offices, angels & HNW. 

Chess strategy image

Leading Advisors

A selected group of leading specialized advisors and consultants with deep subject matter expertise relevant to participants. 

Image by Carlos Gil
PRESENTING COMPANIES

A curated selection of the best, world-class , innovative CNS neurosciences and psychiatric  drug development companies with potential to transform healthcare, patient outcomes or markets.  Selection is by excellence and potential, not by price tag.

There is no cost to present beyond the regular startup or private company registration fees.

Presenting Companies Receive:

- A 3 minute pitch plus 3 minutes of Q&A with an expert panel of relevant investors and industry: In the plenary session.

- Exclusive post presentation meeting space:  

      - Meeting Space: You one of five reserved meeting spaces                   prominently placed next to the main networking area.

      - For 30 minutes in the networking break immediately                          following the presentation session.

- 2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience and psychiatric drug development and biopharma.

- Full access to the summit programme.

- Option to add an exclusive company exhibition stand.

SCHEDULE

Day I -
Feb. 14

08:15 - REGISTRATION OPENS, COFFEE & NETWORKING
09:00 - Official Inauguration and Welcome

09:15 - CNS Neurosciences and Psychiatry – Policy to accelerate a new generation of novel therapeutics.
09:45 - From outward symptoms to underlying biology – where the science is going in ND & psychiatry.
10:30 - COFFEE & NETWORKING BREAK
11:15 - Enhancing patient selection and clinical trials design for rational drug development in ND disease.
12:00 - The move to increasing precision medicine approaches in psychiatric drug development.
12:45 - LUNCH & NETWORKING BREAK
13:45 - Investor Session - The early-stage CNS neuroscience investor perspective. 
14:30 - COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.
15:15 - COFFEE & NETWORKING BREAK
15:45 - Gene Therapy, RNA and Advanced Therapies in Neurodegenerative Disease. 
16:45 - COMPANY PITCH SESSION – Selected startups pitch to an industry & investor panel.
17:30 - END OF DAY I PROGRAM & NETWORKING RECEPTION 

Day II -
Feb. 15

08:15 - REGISTRATION OPENS, COFFEE & NETWORKING
09:00 - Official Inauguration and Welcome

09:15 - Advanced therapeutics in rare neurological diseases; the potential, challenges, and strategies.
10:00 - Growth company panel: Advancing the pipeline and navigating current market conditions.
10:45 - COFFEE & NETWORKING BREAK
11:15 - Industry Panel - Partnering with industry on CNS neuroscience drug development
12:15 - COMPANY PITCH SESSION – 5 Selected startups pitch to an industry & investor panel.
13:00 - LUNCH & NETWORKING BREAK
14:00 - The state of CNS neuroscience drug development, science and investment
14:15 - Biopharma VCs; CNS neuroscience is back
15:00 - Wrap up discussion – Interactive discussion panel between Advisory Board members & participants
15:30 - Bio-Neuroscience Pitch Award – As selected by the investor and industry jury.
15:45 - END OF SUMMIT  -  NETWORKING 

rosarium BAR
Rosarium lobby.jpeg

VENUE

Rosarium

Amstelpark 1, Europaboulevard,

1083 HZ Amsterdam, Netherlands

Rosarium Amstelpark is one of the most presitigious meeting venues in Amsterdam, providing exceptional space for for plenary sessions, meetings and networking. With an open lobby area, wine bar, and adjacent Floriade gardens, it is a unique venue for a high level, by invitation summit like Bio-Neuroscience.  Easily accessible by car (parking available), train, or boat.

Map
By the Water
HOTELS

We suggest that participants reserve in one of the many hotels close to the venue, which you can see in Google Maps above. In particular we recommend the following hotels.  There is no retained travel agent for hotel reservations, so please disregard any unsolicited messages offering official accommodations or bookings; we recommend you book either directly with the hotels or via your preferred online booking site or travel agent. 

  • Novotel Amsterdam City 

    • Europaboulevard 10, 1083 AD Amsterdam

    • Website

  • Van der Valk Hotel Amsterdam - Amstel

    • Joan Muyskenweg 20, 1096 CJ, Amsterdam

  • nhow Hotel Amsterdam RAI

    • ​Europaboulevard 2b, 1078 RV
      Amsterdam

    • Website

CO-ORGANIZED BY

HOST PARTNER

ORGANIZING PARTNER

Organizers
logo-Amsterdam-Neuroscience-2016-1920x365
Broadreach Global logo blue

GOLD SPONSOR
 

WOB-logo-portrait

SILVER SPONSOR
 

Julius Clinical Logo with wordmark.png

PARTNERS & EXHIBITORS

Partners
The_EBC_logo SMALL
Neurospector Logo NEW.png
BrainResearchCenter_logo.png
BID logo
Effectia-Logo.png
PAREA logo.png
ToxGenSolutions logo.png
NeuroSoV-logo.png
PharmaKure logo.png
Enquiries

GET IN TOUCH

Reach us here if you like to

  • Nominate a speaker

  • Apply to present your company or technology

  • Enquire about sponsorship & exhibition opportunities

Thanks, message received. We'll be in touch shortly.

Subscribe

Be the first to know

Subscribe and be among the first to receive all Broadreach Global updates, announcements and invitations.

Please make sure to double check your email address.

Thanks for subscribing!

shutterstock_1707864103 brain scans

A Broadreach Global Initiative

Contact us at: 

Follow us

Broadreach Global Logo white
Copyright © 2023. All rights reserved. Broadreach Global LLC.
  • LinkedIn
bottom of page